Slow And Steady: Merck Advances COVID-19 Antiviral, Vaccine Programs
Q3 Revenue Rises Despite Pandemic’s Impacts On Vaccines Business
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
You may also be interested in...
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
In a broad-ranging interview with Scrip, the ex-CEO of India's Hilleman Laboratories compares the profiles of leading COVID-19 vaccines and urges caution around how far some of the new data now rolling out should be interpreted. The executive also outlines solutions to tackle logistics issues and "vaccine hesitancy" in countries like India.
China’s adherence to face masks to protect against COVID-19 has also helped children avoid other respiratory infections.